via Medical Xpress
A recently developed system for switching on the activity of genes could improve treatments for a broad range of neurological diseases. Esteban Engel, a researcher in viral neuroengineering in the Princeton Neuroscience Institute, and his team have developed new “gene promoters” – which act like switches to turn on gene expression – that promise to broaden the ability to deliver large genes and keep them active for long periods of time.
The research was published online this week in the journal Molecular Therapy: Methods & Clinical Development.
The team is developing these genetic switches for use in gene therapy, the practice of delivering new genes to replace or assist those that are faulty. Gene therapy is a promising strategy for many diseases, including disorders that involve the brain, such as Parkinson’s disease and Alzheimer’s disease.
To carry genes into cells, scientists take advantage of the fact that viruses come equipped with the machinery to gain entry to cells. Over the years, scientists have engineered viruses to deliver genes in ways that are safe and don’t cause disease. One of the viruses commonly used for this is the relatively harmless adeno-associated virus (AAV).
Engel and his team created new gene promoters that turn on genes after they have been transported into neurons – the cells of the brain and nervous system. The team designed their promoters by adopting attributes of promoters found in another class of viruses, the herpes viruses, which persist for years in the body by establishing a chronic infection in the nervous system.
The team’s engineered promoters occupy far less space than existing promoters used in gene therapy, allowing the transport of larger genes or multiple genes. The new promoters are also long-lasting, being less prone to repression or inactivation than most common promoters, so the therapeutic genes are active for long periods of time. These new promoters work with AAV as well as other viral and non-viral gene-delivery systems.
“These new promoters will allow us to deliver larger genes or multiple small genes,” Engel said, “and the genes can remain active for as long as they are needed.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Neurological diseases
- Understanding Neurological Disorders: Symptoms and Causes Explained
Neurological disorders can have a significant impact on an individuals quality of life affecting mobility cognition and overall well-being ...
- Deadly Brain Disease
A deadly neurologic disease has been confirmed in California’s deer and elk population for the first time. Where were they found? The California Department of Fish and Wildlife announced Tuesday that ...
- Significant strides made in Nxera Pharma's oral compound for neurological conditions
Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera ...
- 'Zombie deer' disease detected in California for the first time
The California Department of Fish and Wildlife confirmed two cases of chronic wasting disease in deer this week ...
- This deadly disease that kills deer and elk has been detected in California for the first time
Chronic wasting disease, a fatal illness that spread among deer and elk, was found in two samples in California for the first time.
Go deeper with Google Headlines on:
Neurological diseases
[google_news title=”” keyword=”neurological diseases” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Gene promoters
- Anderson wrestling dynasty began with Gene and Lars
Love him or hate him, Ole Anderson was one of the most believable performers in the history of professional wrestling.
- Freeline Therapeutics Shows Promising Gaucher Disease Gene Therapy Data, Prepares for Phase III
Freeline Therapeutics' lead gene therapy, FLT201, reversed symptoms of Gaucher disease in a Phase I/II trial for up to 38 weeks.
- How Editas 'dragged' Linda Burkly over as CSO after 37 years at Biogen
Linda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore O’Neill—himself an alum of the neurological disease-focused big biotech—came knocking. | Linda Burkly, Ph.D.
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progress
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual Meeting
"First-generation gene therapies for DMD use very high doses of naturally occurring capsids that primarily target the liver, and promoters that are more active in skeletal muscle than heart in ...
Go deeper with Google Headlines on:
Gene promoters
[google_news title=”” keyword=”gene promoters” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]